Clinical Trial Update: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Aficamten versus placebo for symptomatic non-obstructive hypertrophic cardiomyopathy is ongoing but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• Aficamten (aficamten)

Snippet

Sponsor: Cytokinetics | Conditions: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING